Please assess the completion status of the following clinical trial:

Trial Title: Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged between 18 and 45 years, inclusive.~* Body mass index (BMI) between 19 and 30 kg/m2, inclusive.~* Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.~* Negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening~* Clinical laboratory test results clinically acceptable at screening and admission to each treatment period.~* Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period.~* Non-smokers or who smoke ≤ 10 cigarettes or equivalent per day.~* Able and willing to give written informed consent.~* (If female) Not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device.~* (If female) Negative urine pregnancy test at screening and admission to each treatment period.~Exclusion Criteria:~* Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.~* Clinically relevant surgical history.~* History of relevant atopy or drug hypersensitivity.~* History of alcoholism or drug abuse.~* Consumed more than 14 units of alcohol a week.~* Significant infection or known inflammatory process at screening or admission to each treatment period.~* Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period.~* Used medicines within 2 weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion.~* Used any investigational drug or participated in any clinical trial within 6 months prior to screening.~* Participated in more than 2 clinical trials within the 12 months prior to screening.~* Donated or received any blood or blood products within the 3 months prior to screening.~* Vegetarians, vegans or with medical dietary restrictions.~* Could not communicate reliably with the investigator.~* Unlikely to co-operate with the requirements of the study.~* Unwilling or unable to give written informed consent.~* (If female) Pregnant or breast-feeding.~* (If female) Of childbearing potential and she did not use an approved effective contraceptive method (double-barrier or intra-uterine device) or she used oral contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Sequence A (Type: EXPERIMENTAL): Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
- Treatment Sequence B (Type: EXPERIMENTAL): Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period

Based on this trial design, predict the completion outcome and termination type (if applicable).